Promotions and new hire at Astellas
Japanese drug major Astellas Pharma (TYO: $4503) has announced two recent senior-level promotions and one new hire within its Medical and Development (M&D) organization.
Steven Benner was promoted to president and head of Development; Zhonghong Eric Guan has joined Astellas as the senior vice president and head of medical affairs (MA) Americas; and Andrew Krivoshik was promoted to senior vice president and oncology therapeutic area head.
In his new role as senior vice president and head of MA, Americas, Dr Guan will report directly to Charlotte Kremer, executive vice president and head of MA. He will assume overall responsibility for the strategic direction of the MA Americas organization, including continued medical support of in-line products and late-stage development compounds, and translation of medical and patient insights into actionable strategies for Astellas' global medical teams.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze